Fig. 1From: Comparison of immune checkpoint inhibitors related to pulmonary adverse events: a retrospective analysis of clinical studies and network meta-analysisIncidence of pulmonary adverse events (PAEs) in this meta-analysis. a Incidence of PAEs by adverse event level. b Incidence of PAEs according to the treatment class. c Incidence of all-grade PAEs according to the treatment regimen. d Incidence of grades 3–4 PAEs according to the treatment regimenBack to article page